Your weekly update on top ETF trends
 | FRI, SEP 17, 2021 | | | | | | YOUR WEEKLY UPDATE ON TOP ETF TRENDS | | | | The landmines for investors in China keep piling up: a covid-related slowdown in retail sales, hostile U.S. regulators, and Chinese regulators are clamping down on everything from internet companies to online video games and after-school education. What's an international investor to do? Join me Monday at 1 PM ET when my guests will be Arne Noack from DWS, who runs the Xtrackers CSI 300 China A-Shares ETF that tracks the 300 largest and most liquid Chinese shares traded on the Shanghai and Shenzhen exchanges; and Dan Weiner, Chairman of Adviser Investment Management and Editor of the Independent Advisor for Vanguard Investors. ETFedge.cnbc.com. The most commonly asked question: how do I get a higher yield? But that is the wrong question to ask. Yield does not correlate with returns. To get more yield, investors are going all over the world, including to China. The result: a lot of investors are exposing themselves to all kinds of other risks (regulatory risk, geopolitical risk), just to get a few extra basis points in yield. In most cases, it's not worth it. Bet you didn't think you'd see this headline any time soon: the Psychedelices ETF. Our friends at AdvisorShares have rolled out the AdvisorShares Psychedelics ETF (PSIL), which will invest in companies that legally derive at least half of their revenue or assets from psychedelic drugs. Legally? I vaguely remember when 100% of revenues derived from psychedelics was illegal, or am I dating myself? Microdosing is very hot right now. For more analysis and actionable insights, catch me live on Mondays at 1 PM ET on ETF Edge. |
EmoticonEmoticon